Publications by authors named "Virginia Escamilla Gomez"

Ruxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD.

View Article and Find Full Text PDF
Article Synopsis
  • CAR therapy targeting BCMA is being improved with the new anti-BCMA CAR called CARTemis-1, which aims to be more effective against multiple myeloma, addressing the challenges of current treatments that lack sustained effectiveness.
  • The study demonstrated that the longer version of CARTemis-1 showed better cancer-killing ability and confirmed that certain manufacturing conditions, like specific cytokines, enhance CAR-T cell quality and effectiveness.
  • CARTemis-1 was found to be effective without being inhibited by soluble BCMA, and it successfully met regulatory standards for production while exhibiting strong antitumor effects in both lab and live models.
View Article and Find Full Text PDF

Background: Pilot clinical trials have shown the safety of intra-arterial bone marrow mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial BMMNCs in patients with acute stroke has not been tested in a randomised clinical trial. We aimed to show safety and efficacy of two different doses of autologous intra-arterial BMMNC transplantation in patients with acute stroke.

View Article and Find Full Text PDF

Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model.

View Article and Find Full Text PDF

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge.

View Article and Find Full Text PDF

Clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT) from unrelated donors (URDs) approach those of matched related donor (MRD) transplants in patients with acute myeloid leukemia (AML). Yet, available data fail to account for differences in pretransplantation outcomes between these donor selection strategies. In this regard, URD allo-HSCT is associated with longer waiting times to transplantation, potentially resulting in higher probabilities of failure to reach transplant.

View Article and Find Full Text PDF